Physician profile
Robert H Brewer
NPI 1790715308
$9,371.09
in general payments reported to CMS, 2019-2025
23 companies · $418 in 2025
The $418 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,071 · 2020: $304 · 2021: $231 · 2022: $620 · 2023: $742 · 2024: $1,985 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,199 · Travel and Lodging: $946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,199.09 |
| Travel and Lodging | $945.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,912.41 | 2019-2025 | Accolade Sr, Rhythmia Mapping System, Resonate El Icd Vr |
| Medtronic Vascular, INC. | $1,316.89 | 2019-2020 | |
| Medtronic, INC. | $1,195.09 | 2024 | Pulseselect, Arctic Front Advance, Micra |
| Abbott Laboratories | $467.55 | 2019-2025 | Aveir, Ensite, Ensite Precision |
| Pfizer INC. | $275.16 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $259.77 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $235.48 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $147.80 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $143.57 | 2023 | Eliquis, Camzyos |
| Amgen INC. | $82.19 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $52.54 | 2021-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.61 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.48 | 2021-2025 | Lifevest |
| Atricure, INC. | $31.46 | 2024-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Novo Nordisk INC | $30.12 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $24.86 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.76 | 2022 | |
| Stryker Corporation | $21.13 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $18.32 | 2022 | |
| Edwards Lifesciences Corporation | $16.64 | 2024 | Hemosphere |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.08 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.16 | 2021 | |
| Amarin Pharma, INC. | $13.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Brewer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.